A physiologically-based pharmacokinetic model, containing a skin compartment, was derived and used to simulate experimentally determined exposure to m-xylene, using human volunteers exposed under controlled conditions. Biological monitoring was conducted by sampling, in exhaled alveolar air and blood, mxylene and urinary methyl hippuric acid concentrations. The dermal absorption of m-xylene vapor was successfully and conveniently studied using a breath sampling technique, and the contribution to m-xylene body burden from the dermal route of exposure was estimated to be 1.8%. The model was used to investigate the protection afforded by an air-fed, half-face mask. By iteratively changing the dermal exposure concentration, it was possible to predict the ambient concentration that was required to deliver the observed urinary excretion of methylhippuric acid, during and following inhalation exposure to 50 ppm m-xylene vapor. This latter extrapolation demonstrates how physiologicallybased pharmacokinetic modeling can be applied in a practical and occupationally relevant way, and permitted a further step not possible with biological monitoring alone. The ability of the model to extrapolate an ambient exposure concentration was dependent upon human metabolism data, thereby demonstrating the mechanistic toxicological basis of model output. The methyl hydroxylation of m-xylene is catalyzed by the hepatic mixed function oxidase enzyme, cytochrome P450 2E1 and is active in the occupationally relevant, (<100 ppm) exposure range of m-xylene. The use of a scaled-up in vitro maximum rate of metabolism (V maxc ) in the model also demonstrates the increasingly valuable potential utility of biokinetic data determined using alternative, non-animal methods in human chemical-risk assessment.
The common assumption that skin absorption contributes only minor amounts to total uptake, relative to the respiratory tract, is proving to be invalid for an increasing number of occupational and environmentally important chemical liquids and vapors. The dermal route has been reported to be the major contributor to total body burden of polychlorinated biphenyls in some occupational settings (Lees et al., 1987) . Hand contact with liquid xylene for 15 min resulted in the absorbed dose exceeding that obtained from inhalation over a full 8-h shift in car-body repair shop workers (Daniell et al., 1992) . Dermal uptake of 2-butoxyethanol vapor in humans potentially contributes 8 -9% of body burden under resting conditions, assuming that 25% of total skin surface area is exposed (Corley et al., 1997) . Therefore, quantification of the dermal absorption of solvent liquids and vapors is necessary for more accurate assessment and control of health risks.
Biological monitoring (BM) is becoming increasingly important in field studies of exposure and absorption of potential toxicants in the environment, because it provides an integrated estimate of exposure by all routes: respiratory, dermal and oral (Woollen, 1993) . BM has been defined as the measurement of a chemical, or its metabolites, in the body fluids of exposed persons, and conversion to an equivalent absorbed dose of the parent chemical based on a knowledge of its human metabolism and pharmacokinetics (Woollen, 1993) . Conversion to an equivalent absorbed dose of the parent chemical can often be achieved using physiologically based pharmacokinetic (PBPK) modeling. PBPK models are well described and established and increasingly are being used as predictive tools in quantitative chemical risk assessment Andersen and Krishnan, 1994; Clewell et al., 1995; Rowland, 1985) . Due to the definition of specific organs and tissues, organ metabolism, organ transport, and organ-binding properties Gerlowski and Jain, 1983) , PBPK models are a powerful quantitative means of using BM data to calculate the actual absorbed dose (Thomas et al., 1996) . The addition of a dermal compartment to a PBPK model permits the quantitative investigation of chemical absorption through skin (Corley et al., 1997; Mattie et al., 1994; McDougal et al., 1990) . As the dermal route of exposure increases in significance for any given substance, it becomes more likely that routine BM can be undertaken (Jones et al., 1997) .
The present study was undertaken to investigate the utility of a PBPK model in providing a physiologic and mechanistic basis to the biological monitoring of m-xylene. The results reported here are part of a larger study undertaken to establish consistent methodology in order to investigate the potential for dermal uptake from vapors and to provide new and comparative information on a range of substances. M-xylene was one of four chemicals chosen as representative of various classes of chemicals with differing likely contribution to body burden from dermal uptake from vapors, compared to inhalation. The other three chemicals were toluene, 1-methoxypropan-2-ol, and methyl ethyl ketone, the results of which will be reported in due course.
Due to the use of extended shifts in some work places, the model was calibrated and validated using data from a study employing a 2 12-h exposure regime to m-xylene. Human volunteers were subjected to dermal plus inhalation, and dermal-only, exposure to m-xylene vapor. The biokinetics of m-xylene were investigated using blood, breath, and urine samples. A novel breath sampler, developed at the Health and Safety Laboratory, which provides a non-invasive means of monitoring blood concentrations of many solvents and gases was used as part of a wider on-going program of calibrating and validating this instrument .
MATERIALS AND METHODS
Volunteers. The U.K. Health and Safety Executive Research Ethics Committee approved the experimental protocol, and all volunteers provided written informed consent before participating in the study. Four volunteers, 2 male and 2 female (aged 26 to 45) (Table 1) took part, were in good health at the time of the study, did not suffer from respiratory disease, and were not on any medications. Medical assessments were made immediately before the start and at the end of each experiment, to ensure that each volunteer was fit to participate and then to be discharged, respectively. The medical supervisor was present throughout the exposure period. All volunteers were asked to refrain from alcohol consumption for 12 h before, during, and after exposure.
Chemicals. m-xylene (99%) and 3-methylhippuric acid (98%) were purchased from Aldrich Chemical Co. (Dorset, UK). All other chemicals used were reagent grade or higher.
Exposure protocol. Exposures were performed in the Health and Safety Laboratory controlled-atmosphere facility (CAF), a purposely built room of approximately 8-m 3 volume. Atmospheres were generated by introducing m-xylene vapor through purging of m-xylene-filled bubblers with compressed air. The atmospheric concentration within the CAF was monitored continuously by a Miran infra-red spectrophotometer (calibrated by an internal closedloop system) and by gas chromatography (Varian 6000, with a 0.05 m ϫ 0.5 mm interior diameter (i.d.) column, 5% OV10, 100 -120 mesh Chrom CHP packing; injector temperature 120°C; N 2 carrier gas-flow rate 40 ml min Ϫ1 ; oven temperature 60°C) with flame ionization detection (detector temperature 200°C, H 2 flow rate 25 ml min Ϫ1 , air flow rate 300 ml min Ϫ1 calibrated with a dynamic standard atmosphere generator (MDHS 3)). The CAF temperature was maintained at 25°C and 30% humidity for all experiments.
Two studies, designed to simulate different work exposure patterns, were conducted. Study 1 comprised 2 ϫ 12-h exposure periods to 50 ppm m-xylene, separated by a 12-h break. An exposure concentration of 50 ppm was used in order to ensure that the U.K. occupational-exposure standard (OES ) of 100 ppm (8 h time weighted average (TWA)) for m-xylene was not exceeeded. The actual measured concentration for the duration of the experiment was 51 Ϯ 3.25 ppm (CV% [coefficients of variation], 6.37). The volunteers were exposed, at rest, wearing T-shirts and shorts to maximize (with probity) the dermal surface available for vapor contact. Due to the length of the exposure periods, 2 comfort breaks of 30 min each were taken by the volunteers at 4 and 8 h of each 12-h exposure period. The volunteers were allowed food and drink during the comfort breaks.
Study 2 was designed to investigate dermal absorption and consisted of 2 experiments, each comprising 4 h, one a "total" (inhalation and dermal) exposure and the second, a dermal-only exposure to 50 ppm m-xylene vapor. The actual measured concentration for the duration of the experiment was 52 Ϯ 2.30 ppm (CV% 4.42) . The volunteers were exposed at rest wearing T-shirt and shorts as in Study 1. In the dermal-only exposure part of Study 2, volunteers wore air-fed, half-masks (clean air at a flow rate of 120 -150 l min Ϫ1 ) to exclude the inhalation route. Mask inward-leakage, confirmed at Ͻ0.005%, was assessed using the sulphur hexafluoride method (EN:140, 1989) . The exposure regimes are summarized in were exposed simultaneously, with 2 wearing masks and 2 having "total" inhalation.
Biological monitoring. The parameters measured in the three studies are summarized in Table 3 . Due to the discomfort of this procedure, blood sampling was conducted only in Study 1, as data from this part of the investigation was to be used for calibration and validation of the PBPK model. Blood samples were obtained from the antecubital vein with an indwelling canula. The skin surface was cleaned with isopropyl alcohol, which did not interfere with subsequent analytical procedures, prior to venepuncture. In Study 1, blood was removed before, at 1 h intervals during, and at 10, 30, and 60 min post exposure. End-tidal-breath samples (alveolar air) were taken and analyzed according to the method of . Due to the convenience of this method, samples were taken at regular intervals in all studies, as shown in the figures. However, only post exposure breath samples from Study 2 were presented graphically, due to the problems of contamination observed with samples taken in the CAF in Study 1.
For the immediate post-exposure breath sample following dermal-only exposure in Study 2, volunteers took a final breath of solvent-free air via the face mask and then held their breath while leaving the CAF and before providing a sample, in order to reduce the potential for inhalation uptake from contaminated clothing. Clothing was then changed to ensure that further uptake from that source was unlikely. Urine volume was recorded and samples stored at Ϫ20°C until analyzed. Blood samples were stored (48 h maximum) at 4°C as whole blood until analyzed. Blood samples were assayed for m-xylene in duplicate as follows: A 250 l sample was added to 750 l of H 2 O in a 10-ml headspace vial, which was capped with a PTFE-lined rubber septum. The sample was then incubated and continually stirred at 65°C for 10 min. A 1-ml headspace aliquot was taken using a prewarmed (75°C), gas-tight syringe (Fisons HS800 headspace sampler) and analyzed by gas chromatography (Carlo Erba GC8000; column BP-5, 25 m ϫ 0.32 mm id, 5-m film; column head pressure, 50 kPa; carrier gas, helium; oven temperature, 40°C for 1 min, rising by 10°C min Ϫ1 to 140°C for 2 min); and mass spectrometry (Fisons MD800 MS) operating in selected ion-monitoring mode using positive electron ionization (m/z M ϩ 106). The limit of detection of the assay was 0.1 mol l
Ϫ1
with intra-and inter-assay CVs of 5 and 10%, respectively. The major metabolite, methyl hippuric acid (MHA), was measured in urine to assess the rate of biotransformation and elimination of m-xylene. Urine was taken at regular 2-h intervals from 0 -14 h, 22-38, 46 -56, and a final sample at 60 h during Study 1. A 0.5-ml sample of urine was mixed with 0.5 ml methanol and analyzed by HPLC (Hewlett Packard 1050 Series, with autosampler, pump, degasser; column 3 m ODS, 100 ϫ 4.6 mm) with a mobile phase of 0.1% acetic acid:methanol (85:15 with gradient elution), using diode-array detection at a detection wavelength of 230 nm. Samples were assayed in duplicate and quality assurance samples were included with each 5 samples analyzed. The limit of detection of the assay was 40 mol l Ϫ1 with intra-and inter-assay CVs of 2 and 5%, respectively. Urinary creatinine concentrations were measured according to the method of Jaffé (1886).
The PBPK model. The anatomical compartments defined in the model are represented in Figure 1 , and are based on the styrene model by Ramsey and Andersen (1984) . The appropriate human parameters replaced those of the rat. The blood flows and tissue/compartment masses used are similar to those described by Roy et al. (1996) and are listed in Table 4 . The skin represents a mass of 10% body weight and receives 3.4% cardiac output and was described as a lumped parameter, one skin compartment (McDougal et al., 1990; Roy et al., 1996) . Such a model is a simplification of human anatomy where all of the cardiac output perfuses the compartments, while only 92% of the total mass is Blood m-xylene concentration (g 1 Ϫ1 )
Urinary methyl hippuric acid concentration (g g Ϫ1 creatinine)
Schematic of a PBPK model with a skin compartment. The physiologically-based pharmacokinetic model was constructed as described in Materials and Methods and used to simulate the behavior of inhaled and dermally absorbed m-xylene. Cinh is the inhaled concentration, Cexh is the exhaled concentration, Calv is the alveolar concentration, and Ca and Cv are the arterial and venous concentrations of m-xylene, respectively. Q represents blood perfusion of the various compartments which are denoted by: sk, for skin, c, for cardiac output, s, for the slowly perfused tissues, r, for the rapidly perfused tissues, m, for the muscle compartment, f, for the fat compartment and l, for the liver compartment. Vmax, the maximum rate of metabolism and Km, the substrate concentration which gives half the maximum rate of metabolism are the Michaelis-Menten constants describing saturable enzymic metabolism and Kf is first-order metabolism.
defined. The 8% of body mass not discretely defined was regarded as skeletal and structural components with negligible blood perfusion (Ramsey and Andersen, 1984) . The rapidly-perfused tissue group represents kidney, viscera, brain, and other rapidly perfused organs, and the slowly-perfused group represents smooth muscle, cartilage, etc. The muscle group (skeletal), which in other models is included in the slowly-perfused compartment, was separately defined (Arms and Travis, 1988) . The model for m-xylene uptake in humans presented here differs from that of Laparé et al., (1993) , primarily in that metabolic rate constants for hepatic m-xylene metabolism were used, as opposed to a clearance value, and a skin compartment was added to include dermal penetration of vapor.
Dermal penetration of m-xylene was described by a dermal permeability coefficient, calculated using a mathematical skin-permeation model for vapors (Wilschut and ten Berge, 1995) . The surface area of skin exposed was estimated for each volunteer from a human dermal surface area model (Table 1) (DuBois and DuBois, 1916 ). An average estimated skin surface area exposed, of 1.24 m 2 , was used to model the averaged data. This was derived by assuming 58% of total body surface area was exposed.
The model was expanded to describe the rate of MHA production as a proportion of the rate of m-xylene metabolism and is based on a model for metabolite production described in detail elsewhere (Fisher et al., 1989; Loizou et al., 1994) . The amount MHA produced from m-xylene in vivo in humans was reported to be about 93% (Riihimäki et al., 1979) therefore, a stoichiometric yield (SY), 0.93, was used in the model. The apparent volume of distribution, V d , for MHA was not available in the literature and was therefore estimated using the model. The elimination rate constants, K1 and K2, describing the removal of MHA from blood and the appearance of MHA in urine were also estimated using the model, since the values obtained from the literature were composite rate constants and therefore not directly comparable (Åstrand et al., 1978; Engström et al., 1978; Riihimäki et al., 1979; Sedivec and Flek, 1976) . The urinary concentrations of MHA were expressed against creatinine (mg g Ϫ1 ) by dividing the urinary concentrations of MHA (mg l Ϫ1 ) by the averaged experimentally determined urinary creatinine concentration (g l Ϫ1 ). Average values of 92 ml hr Ϫ1 urinary output and creatinine concentration of 1.42 g l Ϫ1 were determined from the 4 volunteers in this study. The Michaelis-Menten constant K m , and first-order metabolism rate constant, K f for m-xylene metabolism in rat were obtained from the literature (Sato and Nakajima, 1979) . The in vitro V maxc ϭ 895 Ϯ 68 (pmol min Ϫ1 mg Ϫ1 ) was scaled-up, using the following parameters for the conversion of m-xylene by the high-affinity metabolism component of human liver microsomes (Tassaneeyakul et al., 1996) . By assuming an average yield of 50 mg microsomal protein per g (wet weight) human liver (Houston, 1994; Houston, B. J., personal communication) and the average liver weight of 2100g in a 70 kg man (3% body weight), a value of 80.6 mmol hr Ϫ1 kg Ϫ1 (8.5 mg hr Ϫ1 kg Ϫ1 ) was obtained. This scaled V maxc value was derived for comparison with the optimized value obtained using the model.
V maxc was also determined using the PBPK model by iterative changes until a good fit to the blood m-xylene concentration data obtained from Study 1 was achieved. This value of V maxc was used a starting value in a statistical optimization software package (ACSL Tox Version 1.1; Mitchell & Gauthier Associates, Inc., Concord, MA, USA) that varied this parameter until a best least-squares fit was achieved. The K m was not varied during these optimiza- tions and is the upper limit for this parameter as discussed by Gargas et al. (1990) .
Partition coefficients (PCs).
Permission from the Clinical Director of the Department of Pathology of the Edinburgh Royal Infirmary was obtained in order to use post-mortem tissue for the determination of tissue:air PCs for m-xylene. Human blood (obtained from laboratory staff) and post-mortem liver, muscle, and fat tissue PCs were determined according to the method of Gargas et al. (1989) . A rat skin:air PC for m-xylene was obtained from the literature (Mattie et al., 1994) and used as a surrogate for the human skin:air PC. Tissue:blood PCs were determined by dividing the tissue:air PCs by the blood:air PC. Surrogate PCs for the slowly and rapidly perfused compartments were obtained from the literature (Laparé et al., 1993) .
RESULTS

Study 1: Venous Blood Concentrations of m-Xylene
During exposure to 50 ppm m-xylene, there was a gradual increase in blood m-xylene concentrations almost reaching a plateau at around 5 h (Fig. 2) . The model satisfactorily simulated blood m-xylene concentrations although it should be noted that the simulation slightly over-predicts the experimental data obtained during the first 4 h. McDougal et al. (1990) , quoting Sato and Nakajima (1979) , reported the following invivo metabolic rate constants for m-xylene metabolism in rats: Figure 2 . This V maxc value is for high-affinity hepatic m-xylene metabolism and compares favorably with a value of 8.5 mg kg Ϫ1 hr Ϫ1 , (80.6 moles kg Ϫ1 hr Ϫ1 ) derived using human liver microsomes (Tassaneeyakul et al., 1996) . Iterative changes to the first-order rate constant, K f from 0 -5.0 hr Ϫ1 had no significant impact on the simulations of venous blood mxylene levels at the exposure concentrations employed in these studies (data not shown). Also, changes in K f had no effect on the urinary excretion of MHA. This is interpreted as there being no evidence for a first-order component of m-xylene metabolism in humans at the exposure concentrations (50 ppm) used in this study. The optimized V maxc value and K m were kept constant throughout the subsequent analyses.
Study 1: Exhalation of m-Xylene
The variability of the experimental data obtained during the 12-h exposure periods may be due to contamination of exhaled breath samples obtained while still in the CAF (Fig. 3) . The CAF atmospheric concentration of m-xylene (50 ppm ϭ 217 g l Ϫ1 ) was approximately 10-fold higher than the concentrations exhaled by the volunteers (Ϸ20 g l Ϫ1 ). The sizes of the standard errors during the first 12-h exposure period are larger and more variable than the second exposure period. Figure 3 shows that the model satisfactorily simulated the alveolar exhalation of m-xylene. Figure 4 shows the profile of MHA excretion expressed against creatinine. Elimination-rate constants for the removal of MHA from blood, k1, and the appearance of MHA in the urine, k2, were: 1.5 hr Ϫ1 (t 1/2 . ϭ 28 min) and 0.9 hr Ϫ1 (t 1/2 . ϭ 46 min), respectively. K1 was more sensitive to iterations than k2, and therefore, determined the slope of the simulation line through the data to a greater extent. The t 1/2 . ϭ 46 min rate for the elimination of MHA in urine is similar, although slightly more rapid, than the half-lives for the initial rapid phase of urinary MHA excretion reported by others (Åstrand et al., 1978; Engström et al., 1978; Riihimäki et al., 1979; Sedivec and Flek, 1976) .
Study 1: Urinary Excretion of Methyl Hippuric Acid
Study 2: Exhalation of m-Xylene following Inhalation and Dermal Exposure
The exhaled concentrations of m-xylene after a 4-h exposure to 50 ppm are similar to those obtained after a 12-h exposure to 50 ppm (Fig. 3) . The post-exposure elimination rate of exhaled alveolar m-xylene from studies 1 and 2 are very similar (t 1/2 ϭ 30 min). This indicates that steady-state conditions in the blood during constant exposure to 50 ppm m-xylene occurs in under 4 h. The model simulated post-exposure exhalation of alveolar air well (Fig. 5) .
Study 2: Dermal-Only Exposure to m-Xylene
The concentrations of m-xylene in exhaled alveolar breath following dermal-only absorption were almost 63-fold lower than those obtained following inhalation and dermal exposure. The skin compartment required a skin:air PC of m-xylene in order to estimate loss from skin. A rat skin:air PC for m-xylene of 50.4 was obtained from the literature (Mattie et al., 1994) and was divided by the human blood:air PC to obtain skin: blood partitioning. Initial simulations showed that the actual rate of elimination of m-xylene via alveolar ventilation was more rapid than model predictions (Fig. 6) . The simulation line was more shallow and passed just above the actual data. The rat skin:air PC was reduced from 50.4 to 30. This assumption was made on the basis that human tissue:air partition coefficients are consistently lower those of the rat (Andersen et al., 1987; Corley et al., 1990; Koizumi, 1989; Lam et al., 1990; Williams et al., 1996) . With a lower skin:air PC the simulation curve passed through the data.
Effect of Inward-Leaking Mask
The model was used to simulate an inward leakage of m-xylene into the masks and therefore potential contamination via the inhalation route during the dermal-only exposure study. This was achieved simply by setting inhalation exposure to a range of possible contaminating concentrations. The masks had an inward leak of 0.005% which is equivalent to 0.0025 ppm during the experiment. However, to test the effect of an inward leak much higher, hypothetical contaminant concentrations were input via the inhalation route (0.1-0.3 ppm). The predicted profile of exhaled m-xylene following dermal-only exposure did not change very much (Fig. 7) . Therefore, the experimentally determined exhaled m-xylene data generated via dermal-only exposure can be taken to be largely uncontaminated by inhaled m-xylene. Estimates made using the model indicate that for m-xylene vapor the dermal route contributes 1.8% of the total dose. Figure 8 further illustrates that the contribution to total body burden via the dermal route of absorption after 50 ppm m-xylene exposure is very small. The inhalation route of exposure was set to 0, while skin exposure was set to 50 ppm. The skin-exposure concentration of m-xylene required to generate the same internal dose as that obtained by inhalation to 50 ppm, and therefore reproduce Figure 4 , was predicted to be 3000 ppm.
DISCUSSION
Study 1: Dermal and Inhalation Exposure
A one-skin-compartment PBPK model was derived and used to investigate human exposure to m-xylene. The experimental data were obtained from a number of exposure scenarios, which were designed to simulate various occupational exposure regimes. Initially, the kinetics of m-xylene in blood during a 12-h constant exposure to 50 ppm were simulated (Fig. 2) . The human exposure data were successfully simulated with in-vitro metabolic rate constants obtained using rat and human tissue. The final scaled value for V maxc ϭ 8.2 mg kg -1 hr -1 (77 mols kg -1 hr -1 ) determined by iteration compared well with an in vitro V maxc ϭ 8.5 mg kg Ϫ1 hr Ϫ1 (80.6 mol kg Ϫ1 hr Ϫ1 ) determined using human microsomes (Tassaneeyakul et al., 1996) . The V maxc value determined by Tassaneeyakul et al. (1996) was described as the high-affinity component of mxylene methyl hydroxylation, which significantly correlated with cytochrome P450 2E1 (CYP2E1) content and activity in human liver microsomes. The involvement of CYP2E1 in the metabolism of m-xylene is consistent with the established important role this enzyme plays in the biotransformation of many low-molecular-weight, lipophilic chemicals (Guengerich and Shimada, 1991; Liira et al., 1991; Nakajima et al., 1991; Loizou and Anders, 1993; Loizou et al., 1994; Olson et al., 1991a,b) .
The model was validated by simulating exhaled alveolar m-xylene and excretion of the major urinary metabolite of m-xylene, MHA (Figs. 3 and 4) . The variability of the exhaled alveolar m-xylene experimental data obtained during the 12-h exposure period may be due to contamination of exhaled breath samples obtained while still in the exposure chamber. There may be two potential sources of contamination of the alveolar sample: (1) from mixing with the remaining dead-space breath, which contained inspired but unabsorbed m-xylene, and (2) from the breath sampler and chamber atmosphere, which could cause the variable increase in m-xylene in the exhaled-breath sample. Also, the volunteers may have been mildly hyperventilating during the first 12-h exposure period. The smaller standard errors of the data from the second 12-h exposure period may be consistent with greater acclimatization. The samples obtained outside of the chamber support this explanation since the standard errors of the data points show little variability.
The elimination half-life for exhalation of alveolar m-xylene immediately post-exposure was estimated to be 30 min, which compares well with the 0.5-1.0 h reported by Riihimäki et al. (1979) . The elimination rate constant used in the model to simulate urinary excretion of MHA was 0.9 hr Ϫ1 , which gives a half-life of 46 min , and is more rapid than the value of 1.9 -5.3 h reported by Engström et al. (1978) . However, Engström et al. (1978) used the standard method to calculate biological half-lives which depends on visually identifying the number of exponential components of a poly-exponential decay curve. The authors identified two phases, rapid and slow elimination, each of which was analyzed by plotting the log of MHA concentration against time. The rapid phase was reported to occur from 0 -10 h and the slow phase from 10 -60 h post exposure. They presented a semi-logarithmic plot of MHA concentration normalized against creatinine versus time, with curves fitted through experimentally determined points obtained at atmospheric exposure concentrations ranging from 1-40 ppm. The appearance of the curves, however, strongly suggests that there are more than 2 phases in the urinary excretion of MHA. This may be expected since 4 phases have been identified for the elimination of toluene from blood (Nise et al., 1989) . The half lives calculated by Engström et al. (1978) are therefore probably composite values comprising a number of first-order elimination rates. A composite elimination rate most likely reflects the temporal metabolism of mxylene to MHA released from different physiological compartments, which have different PCs and perfusion rates. Therefore, the elimination half-life determined by , from which the elimination rate constant can be determined, is not directly comparable with the value used in the PBPK model. There, the single rate constant describes urinary MHA excretion corresponding to the immediate postexposure period. The excretion rate is sufficiently rapid so as not to act as a rate-limiting step in the urinary elimination of MHA in subsequent slower phases. Metabolism of m-xylene to MHA, occurring at different times, due to sequestration in different organs and tissues with different blood perfusion and partitioning, is responsible for the latter slower phases of urinary MHA excretion.
Study 2: Dermal-Only Exposure
Combined inhalation and dermal exposure to 50 ppm mxylene over 4 h was successfully simulated by the model (Fig.  5) . The concentrations of m-xylene in exhaled alveolar air (Ϸ25 g l Ϫ1 ) just prior to the end of exposure and the postexposure elimination rate (t 1/2 ϭ 30 min) were similar to those from Study 1 (Fig. 3) . This suggests that steady state occurs within 4 h, during exposure to 50 ppm m-xylene.
Dermal-only exposure gave rise to exhaled concentrations of alveolar m-xylene which were almost 63 times lower than in combined exposure studies. The effect of the skin:air PC on the rate of elimination of m-xylene via exhalation demonstrates that the skin compartment does have an impact on the delivery of this compound to the blood circulation (Fig. 6 ). It will be interesting to compare the human skin:air PC estimated using the model with an experimentally determined value. The latter depends on the availability of human skin, which is difficult to obtain. Another potential contribution to an improved simulation may be the definition of blood protein and cell binding. Since unbound or free m-xylene would be expected to be exhaled rapidly, it is plausible that there would be a delay in re-establishing the equilibrium between free or unbound, with blood-cell sequestered, and protein-bound m-xylene. Work is currently underway to investigate this possibility. The data presented indicates that the body burden resulting from the dermal-only route can be monitored by this convenient and non-invasive breath sampling technique and is very likely applicable to many other similar substances.
An interesting use of the model was to "back calculate" the dermal exposure concentration necessary to deliver the same body burden generated by inhalation of 50 ppm m-xylene. Figure 8 is the data from Figure 4 , assuming dermal-only exposure to 50 ppm m-xylene and showing that the predicted urinary excretion of MHA is barely discernible. A dermal-only exposure concentration of 3000 ppm was required to produce the same body burden and urinary excretion profile of MHA as shown in Figure 4 . Therefore, an individual wearing an air-fed, face mask exposed to 3000 ppm m-xylene would receive a body burden equivalent to that received after an inhalation exposure to 50 ppm. However, it must be stressed that 3000 ppm m-xylene is a very high exposure concentration that exceeds the U.K. OES of 100 ppm (8 h TWA) and the shortterm exposure limit of 150 ppm (15 min TWA), which are based on the inhalation route and the IDLH (immediately dangerous to life or health) level of 1000 ppm (NIOSH, 1994) . Workers would not normally be exposed to this concentration without breathing apparatus, but what the model shows is that under these conditions the dermal absorption of m-xylene should not be ignored.
